Inhaled budesonide

ApprovedSmall molecule

Inhaled budesonide is one of 91 small molecule programs targeting Bronchopulmonary Dysplasia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Bronchopulmonary DysplasiaActive, not recruiting

Radiation PneumonitisActive, not recruiting

BronchitisActive, not recruiting

PneumoniaActive, not recruiting

Allergic Bronchopulmonary AspergillosisActive, not recruiting

Bronchopulmonary DysplasiaPhase 2

Active, not recruiting

Radiation PneumonitisPhase 2

Active, not recruiting

BronchitisApproved

Active, not recruiting

PneumoniaApproved

Active, not recruiting

Allergic Bronchopulmonary AspergillosisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Inhaled budesonide

UUniversity of British Columbia

Approved

1 2

Primaxin

Pfizer

Preclinical

2 3

Prevacid

Takeda

Preclinical

1 4

Innohep

Alnylam Pharmaceuticals

Preclinical

1 5

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Retrovir

BBp Consulting, Inc

Preclinical

2 7

Zantac 150

CChattem

Preclinical

2 8

Mucinex

AAultman Health Foundation

Preclinical

1 9

Cancidas

FFresenius Kabi Oncology Ltd.

Preclinical

1 10

Piperacillin/tazobactam

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia

Completed·SSara Varea·Phase 4·NCT04355637·120 enrolled

Radiation Pneumonitis1 trial

Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients

Recruiting·IInstituto Nacional de Cancerologia de Mexico·Phase 2·NCT03803787·72 enrolled

Completed·UUniversity of British Columbia·Phase 2/3·NCT00175747·120 enrolled

1 more indication

Bronchopulmonary Dysplasia1 trial

Inhaled Budesonide for Non-ventilated Infants at High Risk of Bronchopulmonary Dysplasia: the i-BUD Pilot Study

Withdrawn·—·Phase 2·NCT01895075

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Inhaled budesonide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Inhaled budesonide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Inhaled budesonide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of British Columbia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: UUniversity of British Columbia

Inhaled budesonide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

Radiation Pneumonitis1 trial

Allergic Bronchopulmonary Aspergillosis1 trial

Bronchitis1 trial

Budesonide1 trial

Bronchopulmonary Dysplasia1 trial

References

Drug Info

Quick Facts

Related News